VYNE Therapeutics (NASDAQ:VYNE) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded shares of VYNE Therapeutics (NASDAQ:VYNE) from a hold rating to a sell rating in a research report sent to investors on Thursday.

Separately, HC Wainwright decreased their price objective on shares of VYNE Therapeutics from $5.75 to $4.50 and set a “buy” rating on the stock in a research report on Friday, April 25th.

VYNE Therapeutics Stock Performance

VYNE stock opened at $1.00 on Thursday. The firm’s 50-day moving average price is $1.53 and its two-hundred day moving average price is $2.32. VYNE Therapeutics has a 12-month low of $0.99 and a 12-month high of $4.30. The stock has a market capitalization of $15.21 million, a price-to-earnings ratio of -1.16 and a beta of 1.76.

VYNE Therapeutics (NASDAQ:VYNE) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.09. VYNE Therapeutics had a negative net margin of 6,896.55% and a negative return on equity of 43.73%. The firm had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.05 million. Equities analysts predict that VYNE Therapeutics will post -0.97 EPS for the current year.

Institutional Investors Weigh In On VYNE Therapeutics

A number of large investors have recently modified their holdings of the stock. Acorn Capital Advisors LLC boosted its stake in shares of VYNE Therapeutics by 72.0% during the 1st quarter. Acorn Capital Advisors LLC now owns 785,938 shares of the company’s stock valued at $1,242,000 after purchasing an additional 328,968 shares in the last quarter. Exome Asset Management LLC boosted its stake in shares of VYNE Therapeutics by 30.9% during the 1st quarter. Exome Asset Management LLC now owns 462,801 shares of the company’s stock valued at $731,000 after purchasing an additional 109,367 shares in the last quarter. Parkman Healthcare Partners LLC boosted its stake in shares of VYNE Therapeutics by 42.5% during the 1st quarter. Parkman Healthcare Partners LLC now owns 217,978 shares of the company’s stock valued at $344,000 after purchasing an additional 65,005 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in shares of VYNE Therapeutics by 123.3% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 344,134 shares of the company’s stock valued at $544,000 after purchasing an additional 190,000 shares in the last quarter. Finally, ADAR1 Capital Management LLC bought a new stake in shares of VYNE Therapeutics during the 1st quarter valued at about $111,000. Institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.